Search studies
13 studies found
Smart4Health Citizen-Provided data
259d96fe-2af3-4a78-92d3-f5570c09475f
The purpose of the Smart4Health project is to develop and evaluate the prototype of the Smart4Health platform for the upload and storing of citizens' health-related data, and to offer it as a service. The Smart4Health service providing various features allows to manage and selectively share citizens' data using a web browser on mobile devices or computers. Both development and evaluation of the Smart4Health platform and service are meant to be citizen-centred, thus involving users in order to...
ABI-MS
91f1a748-c48e-11ec-9b1d-acde48001122
Patients with MS or Clinically Isolated Syndrome (CIS) diagnosis according to McDonald criteria and who were prescribed IFN-beta-1a intramuscularly (IM), IFN-beta-1a subcutaneously (SC), or IFN-beta-1b SC (original product or biosimilar) were recruited from January 30, 2014 to January 22, 2016. Patients who were not naive to IFN-beta were excluded.
PRECISESADS: Cross Sectional Study - Lupus patients ...
ELU-4-32DBAB-1
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Cross Sectional Study
PRECISESADS: Mice Study - Spontaneous mouse models a...
ELU-4-4096E6-1
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Mouse models
PRECISESADS: Cross Sectional Study & Inception Cohort
ELU-4-9E5405-1
The goal of this project is to use the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them of potential benefits in terms of the use of new therapeutic agents that are being developed for one disease but cannot be applied in another, due to current clinical classifications. We will investigate individuals with systemic lupus erythematosus ...
ABI-RA
b4c2e822-c48e-11ec-9b1d-acde48001122
Patients with RA diagnosis according to 2010 ACR/EULAR criteria and who were prescribed for the first time a BP among the TNF inhibitors adalimumab, infliximab (original product or biosimilar), etanercept, the anti-CD20 antibody rituximab, or the anti-IL6R antibody tocilizumab (administered SC or intravenously) as first-line or second-line therapy were recruited from March 3, 2014 to June 21, 2016. Patients who were not naive for the biotherapy they were given in the study were excluded.
ABI-IBD
b4c2ea0c-c48e-11ec-9b1d-acde48001122
Patients with Crohn’s disease or ulcerative colitis diagnosis according to ECCO guidelines and who were prescribed adalimumab or infliximab (original product or biosimilar) were recruited from September 11, 2013 to February 15, 2016. Patients who were not naive to TNF inhibitor therapy or who were treated with corticoids more than 30 mg/day over the last 15 days were excluded.
APPROACH source cohorts
dc9a475c-147a-11eb-b51f-8c8590c45a21
All baseline cohort parameters, clinical, conventional (knee x-ray and MRI and the robust biochemical markers), and novel markers (T2 relaxation MRI for cartilage collagen distribution, gagCEST MRI cartilage for proteoglycan content, knee CT/x-ray for bone shape and trabecular architecture, knee motion, and novel biochemical markers describing turnover of specific tissue component, as well as involvement of hand, hip and spine joint damage, hand joint inflammation, hip motion and shape and bo...
